ArticleThe Journal of experimental medicine2003
BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells.
Article in The Journal of experimental medicine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 98 citations in OpenAlex.
- Trial
- Rewiring tumor immunity via zinc finger proteins: a new frontier in cancer immunotherapy.Journal of translational medicine · 2025Review
- Genetic deregulation of REL in germinal center B cells induces generation of a pool of lymphoma precursor cells.Blood advances · 2025Article
- Germinal Center B Cells are Uniquely Targeted by Antibody-Suppressor CXCR5Transplantation direct · 2025Article
- Interleukin-4 downregulates transcription factor BCL6 to promote memory B cell selection in germinal centers.Immunity · 2024Article
- Delineating the mechanism of fragility at BCL6 breakpoint region associated with translocations in diffuse large B cell lymphoma.Cellular and molecular life sciences : CMLS · 2024Article
- NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer.Communications biology · 2021Article
- Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.Medical oncology (Northwood, London, England) · 2021Article
- Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis.Science translational medicine · 2020Article
- The PI3K pathway impacts stem gene expression in a set of glioblastoma cell lines.Journal of cancer research and clinical oncology · 2020Article
- miR-144-3p inhibits cell proliferation of colorectal cancer cells by targeting BCL6 via inhibition of Wnt/β-catenin signaling.Cellular & molecular biology letters · 2020Article
- PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription.Nucleic acids research · 2019Article
- Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s.JCI insight · 2019Article
- Regulation of the Development and Function of B Cells by ZBTB Transcription Factors.Frontiers in immunology · 2018Review
- Review
- p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.Molecular cancer research : MCR · 2017Article
- An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation.PLoS pathogens · 2017Article
- Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.The Journal of biological chemistry · 2016Article
- Survivin co-ordinates formation of follicular T-cells acting in synergy with Bcl-6.Oncotarget · 2015Article
- Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.Toxicological sciences : an official journal of the Society of Toxicology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The BCL6 proto-oncogene encodes a transcriptional repressor required for the development of germinal centers (GCs) and implicated in the pathogenesis of GC-derived B cell lymphoma. Understanding the precise role of BCL6 in normal GC formation and in lymphomagenesis depends on the identification of genes that are direct targets of its transcriptional repression. Here we report that BCL6 directly controls the expression of B7-1/CD80, a costimulatory receptor involved in B-T cell interactions critical for the development of T cell-mediated antibody responses. Upon CD40 signaling, transcription of the CD80 gene is induced by the nuclear factor (NF)-kappaB transcription factor. Our results show that BCL6 prevents CD40-induced expression of CD80 by binding its promoter region in vivo and suppressing its transcriptional activation by NF-kappaB. Consistent with a physiologic role for BCL6 in suppressing CD80, the expression of these two genes is mutually exclusive in B cells, and BCL6-defective mice show increased expression of CD80 in B cells. The results suggest that BCL6 may directly control the ability of B cell to interact with T cells during normal GC development. In addition, these findings imply that T-B cell interactions may be disrupted in B cell lymphoma expressing deregulated BCL6 genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.